NCT04284852View on ClinicalTrials.gov

Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 1, 2020

Primary Completion Date

October 1, 2023

Study Completion Date

October 1, 2023

Conditions
Ovarian Cancer
Interventions
DRUG

Niraparib

PARP inhibitor

Trial Locations (1)

Unknown

The University of Hong Kong, Hong Kong

All Listed Sponsors
lead

The University of Hong Kong

OTHER

NCT04284852 - Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting | Biotech Hunter | Biotech Hunter